Procedure
|
Baby hospitalisation
|
---|
Screeninga
|
Trial entry and treatment (days 1−3)
|
Up to 7 days after trial medication
|
3 weeks of age
|
36 weeks of PMA
|
Discharge
|
---|
Demographyg
| |
✓
| | | |
✓
|
Echocardiogram/colour Dopplerf
|
✓
| | |
✓
| | |
Confirmation of eligibility
|
✓
| | | | | |
Consent
| |
✓
| | | | |
Randomisationb
| |
✓
| | | | |
Ibuprofen/placebo dosingc
| |
✓
| | | | |
IVH/PVL ultrasound scansh
| | |
✓
| |
✓
| |
NEC
| | | | | |
✓
|
Oxygen reduction test
| | | | |
✓
| |
SAEsd
| |
✓
|
✓
| | | |
Concomitant medicatione
|
✓
|
✓
| |
✓
|
✓
|
✓
|
- aScreening assessments to be completed sufficiently in advance to enable randomisation and dosing within 72 h of birth. If consent cannot be obtained before echocardiographic evaluation for eligibility, echocardiographic assessment should continue, and consent obtained when possible if a baby is deemed eligible
- bRandomisation to be completed sufficiently in advance to enable dosing within 72 h of birth
- cInitial trial drug administrations to be given soon after randomisation, after 6 h of age and within 72 h of birth. Subsequent doses to be administered 24 h after the initial dose
- dOnly adverse events which are serious will be recorded from first dose until 7 days after trial medication. Only unforeseeable SAEs will be reported
- eConcomitant medications to be recorded only in relation to unforeseeable SAEs. In the event of an unforeseeable SAE all concomitant medication, including medication given to the baby’s mother, 7 days prior to the onset of the event to the time of its resolution must be recorded on the SAE form
- fAn echocardiogram scan will be performed when the baby reaches around 3 weeks of age (range of 18–24 days) or at hospital discharge if discharged earlier
- gDemography and medications will be assessed through the PARCA-R and other questionnaires
- hIf a baby transfers from the recruiting site to a continuing care site for on-going care details of any scan would be helpful